Age-related muscle loss stems from disrupted balance between mTOR (mammalian target of rapamycin) anabolic signaling and myostatin catabolic pathways, compounded by hormonal decline, insulin resistance, and mitochondrial dysfunction that create "anabolic resistance" in older adults. This mechanistic understanding transforms how we approach muscle preservation strategies. The mTOR pathway, essential for protein synthesis, becomes increasingly resistant to stimulation with age, while myostatin continues degrading muscle tissue. This creates a metabolic imbalance favoring muscle loss over maintenance. The clinical implications are profound for the growing aging population. Rather than viewing sarcopenia as inevitable, this pathway-focused approach suggests targeted interventions could restore anabolic sensitivity. Multimodal strategies combining resistance training (which activates mTOR), optimized protein timing and leucine intake (mTOR stimulators), and potential myostatin inhibitors represent a precision medicine approach to muscle preservation. The research underscores that successful aging requires proactive muscle mass management, not reactive treatment. While the mechanisms are well-established, translating this knowledge into widely accessible interventions remains the critical next step for population health.